Consolidated Guidelines

Web Annex G. Mycobacterium tuberculosis antigen-based skin tests: evidence-to-decision table

Web Annex F. Qualitative evidence for the use of Mycobacterium tuberculosis antigen-based skin tests

Web Annex E. Modelling for economic evidence for the use of Mycobacterium tuberculosis antigen-based skin tests

Web Annex D. Cost–effectiveness of Mycobacterium tuberculosis antigen-based skin tests: a systematic review

Web Annex C. GRADE profiles of Mycobacterium tuberculosis antigen-based skin tests

Web Annex B. Safety of Mycobacterium tuberculosis antigen-based skin tests: a systematic review and meta-analysis

Web Annex A. Accuracy of Mycobacterium tuberculosis antigen-based skin tests: a systematic review and meta-analysis

Before being considered for group membership, each candidate for the Guideline Development Group (GDG) and External Review Group (ERG) was required to submit a completed declaration of interest (DOI) form. In addition, a preliminary internet search was performed to identify any obvious public controversies or interests that might lead to compromising situations for the World Health Organization (WHO) and the expert concerned.

For every GDG meeting PICO questions were drafted by the WHO steering group and were presented to the respective GDG for discussion and modification. The WHO steering group has been making an initial list of patient-important outcomes, including desirable and undesirable effects and has solicited feedback from the Guideline Development Group to identify any other outcomes. The outcomes were further rated, according to the procedure described in WHO handbook for guideline development (2nd edition)⁷